Biblio Discovery — Demo Discovery Service

4 hasil untuk "H. Beverloo"

Menampilkan 1–4 · 0,55 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Technical Note: Wet validation of optical tomography for drinking water discolouration studies

    R. Floris; P. van Thienen; H. Beverloo

    Drinking Water Engineering and Science, Vol. 6 No. 1 · 2013 · Inggris · DOAJ

    This paper presents a set of validation experiments for the reconstruction of a cross-sectional particle concentration field in a transparent pipe filled with a fluid using optical tomography.

  2. Artikel Jurnal Teks lengkap

    A bottom-up approach of stochastic demand allocation in water quality modelling

    E. J. M. Blokker; J. H. G. Vreeburg; H. Beverloo dkk.

    Drinking Water Engineering and Science, Vol. 3 No. 1 · 2010 · Inggris · DOAJ

    An "all pipes" hydraulic model of a drinking water distribution system was constructed with two types of demand allocations. One is constructed with the conventional top-down approach, i.e. a demand multiplier pattern from the booster station is allocated to all demand nodes with a correction…

  3. Artikel Jurnal

    Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin

    Dimitrios Kotsos; Patrycja Gradowska; Sjoerd J.F. Hermans dkk.

    Haematologica, Vol. 999 No. 1 · 2026 · Inggris · DOAJ Scopus

    Therapy-related acute myeloid leukemia (t-AML) and AML with myelodysplasia-related changes (AML-MRC) are associated with poor outcomes. The liposomal formulation of cytarabine and daunorubicin (CPX-351) improved complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates and…

  4. Artikel Jurnal

    Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

    Meral Beksac; Tulin Fıratlı Tuglular; Francesca Gay dkk.

    HemaSphere, Vol. 10 No. 1 · 2026 · Inggris · DOAJ Scopus

    ABSTRACT Novel therapies are needed for patients with multiple myeloma (MM) and extramedullary plasmacytomas. The prospective, Phase II EMN19 study assessed the efficacy and safety of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (DaraVCD) in 40 patients with newly diagnosed MM…